AstraZeneca PLC (LSE:AZN) Annual Report 2021



The latest annual report of AstraZeneca PLC (AZN) was published on 31 Dec 2021. An annual report is a document that public corporations must provide annually to shareholders that describes their operations and financial conditions. Typically, an annual report will contain sections such as General corporate information, Operating and Financial highlights, Letter to shareholders from the CEO, Financial statements etc.

Key Statistics - AZN Annual Results

Amounts in USD

Total Revenue
37.42B
Gross Profit
27.61B
EBIT
4.57B
Net Tangible Assets
-23.12B
Net Income
112M
Capital Expenditures
-1.09B

AZN Income Statement 2021 Annual Report

As per the latest Income Statement of AZN, the Net revenue increased by $10.8B (41%) compared to the previous period. The operating income in 2021 increased by $421.00M (10%). The net income as per the annual report was 112M which decreased by $-3.084B (-96%) compared to previous year.

Income Statement Report (2021/2020)

20212020
Total Revenue37.42B26.62B
Gross Profit27.61B21.37B
Operating Income4.57B4.15B
Income Before Tax-265M3.92B
Net Income112M3.2B

Balance Sheet - AZN 2021 Annual Report

Read further: AZN Balance Sheet Detailed Analysis

The latest balance sheet from annual result of AstraZeneca PLC showed the company reduced the cash on balance sheet by $-1.503B (-19%). The Net tangible assets of AZN on the balance sheet were at -23.12B which is $-5.946B (-35%) less than previous annual report. The total stockholder equity also increased by $23.646B (151%) compared to previous reporting period.

Balance Sheet Statement Report (2021/2020)

20212020
Cash6.33B7.83B
Total Assets105.36B 66.73B
Long Term Debt29.72B19.8B
Total Liabilities66.08B 51.09B
Total Shareholder Equity39.27B15.62B
Net Tangible Assets-23.12B-17.17B

Cash Flow Statement - AZN 2021 Annual Report

The 2021 annual cash flow statement of AstraZeneca PLC showed that the net income decreased by $-3.084B (-96%) compared to previous reporting period. Also the capital expenditure of AZN decreased by $-130.00M (-14%).

As of 2021, the total cash from investing activities was -11.06B and total cash from financing activities was 3.65B.

Cash Flow Statement Report (2021/2020)

20212020
Net Income112M3.2B
Capital Expenditures-1.09B-961M
Dividends Paid-3.86B-3.57B
Total Cash From From Investing Activities-11.06B-285M
Total Cash From From Financing Activities3.65B-2.2B

AstraZeneca PLC Annual Report History

Income Statement

Income Statement history of AstraZeneca PLC (LSE:AZN)

31 Dec 202131 Dec 202031 Dec 201931 Dec 2018
Total Revenue37.42B26.62B24.38B22.09B
Cost Of Revenue9.81B5.25B4.85B4.5B
Gross Profit27.61B21.37B19.54B17.59B
Research Development8.58B6.12B5.35B5.3B
Selling General Administrative14.67B11.59B11.44B10.82B
Non Recurring----
Other Operating Expenses-207M-486M-319M-266M
Total Operating Expenses32.85B22.47B21.32B20.36B
Operating Income4.57B4.15B3.07B1.73B
Total Other Income Expense Net-4.83B-232M-1.52B262M
Ebit4.57B4.15B3.07B1.73B
Interest Expense-776M-738M-780M-744M
Income Before Tax-265M3.92B1.55B1.99B
Income Tax Expense-380M772M321M-57M
Minority Interest19M16M1.47B1.58B
Net Income From Continuing Ops115M3.14B1.23B2.05B
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Charges----
Other Items----
Net Income112M3.2B1.33B2.15B
Net Income Applicable To Common Shares112M3.2B1.33B2.15B

Balance Sheet Statement

Balance Sheet Statement history of AstraZeneca PLC (LSE:AZN)

31 Dec 202131 Dec 202031 Dec 201931 Dec 2018
Cash6.33B7.83B5.37B4.83B
Short Term Investments53M42M38M40M
Net Receivables8.79B5.65B5.18B4.84B
Inventory8.98B4.02B3.19B2.89B
Other Current Assets556M99M106M1.24B
Total Current Assets26.24B19.54B15.56B15.59B
Long Term Investments1.26B1.19B1.51B978M
Property Plant Equipment10.17B8.92B8.34B7.42B
Good Will20B11.85B11.67B11.71B
Intangible Assets42.39B20.95B20.83B21.96B
Other Assets5.3B4.28B3.47B3B
Deferred Long Term Asset Charges4.33B3.44B2.72B2.38B
Total Assets105.36B66.73B61.38B60.65B
Accounts Payable2.82B2.35B1.77B1.72B
Short Long Term Debt1.33B1.57B1.63B1.03B
Other Current Liab5.44B5.85B4.9B3.73B
Long Term Debt29.72B19.8B17.89B19.2B
Other Liab13.01B10.49B10.28B11.11B
Minority Interest19M16M1.47B1.58B
Total Current Liabilities22.59B20.31B18.12B16.29B
Total Liab66.08B51.09B46.78B46.61B
Common Stock387M328M328M317M
Retained Earnings3.64B6.44B5B7.69B
Treasury Stock111M881M-143M34M
Capital Surplus35.13B7.97B7.94B4.43B
Other Stockholder Equity111M881M-143M34M
Total Stockholder Equity39.27B15.62B13.13B12.47B
Net Tangible Assets-23.12B-17.17B-19.37B-21.2B

Cash Flow Statement

Cash Flow Statement history of AstraZeneca PLC (LSE:AZN)

31 Dec 202131 Dec 202031 Dec 201931 Dec 2018
Net Income112M3.2B1.33B2.15B
Depreciation4.04B2.83B2.71B2.73B
Change To Netincome-272M-1.65B-802M-1.71B
Change To Account Receivables-961M-739M-898M-523M
Change To Liabilities1.41B1.72B868M-103M
Change To Inventory1.58B-621M-316M-13M
Total Cash From Operating Activities5.96B4.8B2.97B2.62B
Capital Expenditures-1.09B-961M-979M-1.04B
Investments605M2B125M140M
Other Cashflows From Investing Activities54M87M274M193M
Total Cashflows From Investing Activities-11.06B-285M-657M963M
Dividends Paid-3.86B-3.57B-3.59B-3.48B
Net Borrowings7.65B1.44B-1.7B1.47B
Other Cashflows From Financing Activities-178M-101M4M-67M
Total Cash From Financing Activities3.65B-2.2B-1.76B-2.04B
Effect Of Exchange Rate-62M12M5M-38M
Change In Cash-1.51B2.32B552M1.5B
Issuance Of Stock29M30M3.52B34M